14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation

14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation

Intraoperative fluid management has evolved from unmonitored empirical fluid replacement toward individualized, physiology-guided therapy. Both hypovolemia and hypervolemic fluid overload cause substantial perioperative morbidity. Understanding fluid compartmental kinetics, the physical chemistry of crystalloid solutions, dynamic hemodynamic indices, and the three pillars of Patient Blood Management is essential for modern anaesthetic practice.

---

1. Physiological Fluid Compartments and the Endothelial Glycocalyx

Fluid Compartment Anatomy

In an average adult male, Total Body Water (TBW) constitutes approximately $60\%$ of total body weight ($42\text{ L}$ in a $70\text{ kg}$ adult). In adult females, higher adipose content reduces TBW to approximately $50\%$ ($35\text{ L}$ in a $70\text{ kg}$ adult). In neonates, TBW reaches $75-80\%$.

                         [ TOTAL BODY WATER (TBW) ]
                         (60% of Body Weight: ~42 L)
                                      |
        +-----------------------------+-----------------------------+
        |                                                           |
  [ Intracellular Fluid (ICF) ]                               [ Extracellular Fluid (ECF) ]
  (2/3 of TBW: ~28 L / 40% BW)                                (1/3 of TBW: ~14 L / 20% BW)
  Major ions: K+, Mg2+, PO4(3-), Proteins                     Major ions: Na+, Cl-, HCO3-
                                                                            |
                                              +-----------------------------+-----------------------------+
                                              |                                                           |
                                [ Interstitial Fluid (ISF) ]                                [ Intravascular Plasma ]
                                (3/4 of ECF: ~10.5 L / 15% BW)                              (1/4 of ECF: ~3.5 L / 5% BW)

• Intracellular Fluid ($ICF$): Two-thirds ($2/3$) of TBW ($\approx 40\%$ of body weight, $\approx 28\text{ L}$). High concentrations of potassium ($K^+ \approx 140-150\text{ mmol/L}$), magnesium, organic phosphates, and proteins.
• Extracellular Fluid ($ECF$): One-third ($1/3$) of TBW ($\approx 20\%$ of body weight, $\approx 14\text{ L}$). High concentrations of sodium ($Na^+ \approx 140\text{ mmol/L}$) and chloride ($Cl^- \approx 100\text{ mmol/L}$). The $ECF$ is subdivided into:
  • Interstitial Fluid ($ISF$): Three-fourths ($3/4$) of $ECF$ ($\approx 15\%$ of body weight, $\approx 10.5\text{ L}$).
  • Intravascular Plasma Volume: One-fourth ($1/4$) of $ECF$ ($\approx 5\%$ of body weight, $\approx 3.5\text{ L}$). Adding red blood cell volume ($\approx 2.0\text{ L}$) yields a total circulating blood volume of $\approx 5.0-5.5\text{ L}$ ($70\text{ mL/kg}$ in adult males, $65\text{ mL/kg}$ in females).

The Endothelial Glycocalyx Layer (EGL)

The revised Starling principle recognizes that transvascular fluid filtration occurs across the endothelial glycocalyx layer—a delicate, $0.5-1.0\text{ }\mu\text{m}$ thick meshwork of membrane-bound proteoglycans (syndecans, glypicans) and glycosaminoglycans (heparan sulfate, chondroitin sulfate, hyaluronic acid) coating the luminal surface of healthy vascular endothelium.

• The glycocalyx maintains vascular barrier competence, prevents leukocyte and platelet adhesion, and restricts protein extravasation.
• Disruption of the Glycocalyx: Hypervolemia (via atrial natriuretic peptide / ANP release triggered by atrial stretch), acute hyperglycemia, ischemia-reperfusion injury, sepsis, and major surgical trauma strip the glycocalyx. Once destroyed, intravenous crystalloids and colloids rapidly leak directly into the interstitial space, causing severe tissue edema, impaired microcirculatory oxygen delivery, and prolonged postoperative ileus.

---

2. Crystalloids versus Colloids: Electrolyte Compositions and Acid-Base Physics

Stewart Physical-Chemical Acid-Base Model & Normal Saline

Under Peter Stewart's quantitative acid-base theory, plasma $[H^+]$ and $[HCO_3^-]$ are dependent variables dictated by three independent variables:

1. The Strong Ion Difference ($SID = \sum [\text{Strong Cations}] - \sum [\text{Strong Anions}]$): $SID = ([Na^+] + [K^+] + [Ca^{2+}] + [Mg^{2+}]) - ([Cl^-] + [\text{Other Strong Anions}])$ Normal plasma $SID$ is approximately $38-42\text{ mEq/L}$.
2. Total weak non-volatile acids ($A_{\text{tot}}$, primarily albumin and phosphate).
3. Partial pressure of carbon dioxide ($Pa\text{CO}_2$).

The Pathophysiology of 0.9% Normal Saline

Although historically termed "physiological saline", $0.9\%\text{ NaCl}$ is profoundly non-physiological:

• It contains $154\text{ mmol/L}$ of $Na^+$ and $154\text{ mmol/L}$ of $Cl^-$, with a $SID = 0\text{ mEq/L}$.
• Infusion of large volumes of saline floods the plasma with supranormal chloride concentrations, drastically reducing the patient's plasma $SID$. To maintain electrical neutrality, water dissociates into $H^+$ ions, and plasma bicarbonate concentration falls precipitously, producing hyperchloremic metabolic acidosis with a normal anion gap.
• Renal Hemodynamic Sequelae: Hyperchloremia causes increased chloride delivery to the macula densa in the juxtaglomerular apparatus, triggering tubuloglomerular feedback. This induces profound renal afferent arteriolar vasoconstriction, reducing renal cortical blood flow, decreasing glomerular filtration rate ($GFR$). In the SMART trial (2018), balanced crystalloids modestly reduced major adverse kidney events within 30 days compared with saline, although the larger BaSICS and PLUS trials found no difference in mortality.

Balanced Crystalloids: Hartmann's and Plasmalyte

Balanced crystalloids replace excess chloride with metabolizable organic anions (lactate in Hartmann's; acetate and gluconate in Plasmalyte). These anions are rapidly metabolized (lactate by the liver via gluconeogenesis; acetate and gluconate by peripheral skeletal muscle), generating bicarbonate and maintaining a physiological $SID$ of $28-50\text{ mEq/L}$, which largely avoids hyperchloremic acidosis.

Synthetic Colloids: Hydroxyethyl Starches (HES)

Synthetic colloids (hydroxyethyl starches, gelatins, dextrans) were developed to achieve prolonged intravascular volume expansion. However, multi-center randomized controlled trials in critically ill patients (VISEP, 6S, CHEST) established that hydroxyethyl starches (HES):

1. Accumulate in the reticuloendothelial system and renal tubular epithelial cells, causing osmotic nephrosis and a significantly increased requirement for renal replacement therapy (dialysis).
2. Disrupt normal hemostasis by diluting clotting factors, accelerating fibrinolysis, and acquiring von Willebrand syndrome / Factor VIII deficiency.
3. Trigger severe, intractable pruritus. Consequently, the US FDA added a boxed warning (2013, strengthened in 2021), and in 2022 the European Medicines Agency recommended suspending HES marketing authorisations across the EU. Natural colloids (5% and 20% human albumin) remain indicated for large-volume paracentesis, severe hypoalbuminemia with septic shock, and select resuscitation contexts where crystalloid volume limits are exceeded.

---

3. Goal-Directed Hemodynamic Therapy (GDHT) and Dynamic Indices

Goal-Directed Hemodynamic Therapy (GDHT) utilizes continuous stroke volume monitoring to titrate intravenous fluids, vasopressors, and inotropes toward defined physiological targets, optimizing cellular oxygen delivery while avoiding fluid overload.

                       [ THE FRANK-STARLING MECHANISM ]

       Stroke Volume (SV)
              ^
              |                      Preload-Independent (Plateau)
              |                                 /---------------
              |                                /  (Fluid Non-Responder)
              |                               /
              |                              /
              |      Preload-Dependent      /
              |      (Fluid Responder)     /
              |                           /
              |                          /
              +-------------------------+-------------------------> Preload (EDV)

Dynamic Indices: SVV and PPV

Static markers of intravascular volume (central venous pressure / CVP, pulmonary capillary wedge pressure / PCWP) fail to predict fluid responsiveness. In contrast, dynamic arterial indices exploit cyclic variations in intrathoracic pressure induced by mechanical ventilation to assess whether the heart is operating on the steep (preload-dependent) or flat (preload-independent) portion of the Frank-Starling curve.

$\text{Stroke Volume Variation (SVV)} = \frac{SV_{\max} - SV_{\min}}{(SV_{\max} + SV_{\min}) / 2} \times 100$ $\text{Pulse Pressure Variation (PPV)} = \frac{PP_{\max} - PP_{\min}}{(PP_{\max} + PP_{\min}) / 2} \times 100$

• Threshold Value: An $\text{SVV} > 12-13\%$ or a $\text{PPV} > 13\%$ strongly predicts that the patient is fluid-responsive (i.e., administering a fluid bolus of $250-500\text{ mL}$ of balanced crystalloid will increase stroke volume by $>10-15\%$).

The 5 Strict Prerequisites for Valid SVV and PPV Interpretation

Dynamic indices are invalid if any of the following 5 criteria are violated:

1. Regular Sinus Rhythm: Arrhythmias (atrial fibrillation, frequent ectopy) generate beat-to-beat stroke volume variations unrelated to respiration.
2. Closed Thoracic Cavity: Open thoracotomy or sternotomy abolishes cyclic intrathoracic pressure swings.
3. Fully Controlled Mechanical Ventilation: Absence of any spontaneous respiratory efforts; spontaneous inspiratory efforts generate negative intrathoracic pressures, producing erratic arterial waveform swings.
4. Adequate Tidal Volume: Requires a mandatory tidal volume of $\ge 8\text{ mL/kg}$ of ideal body weight (IBW). Low tidal volume protective ventilation ($6\text{ mL/kg}$) generates insufficient intrathoracic pressure swings, causing false-negative readings.
5. Normal Lung and Chest Wall Compliance: Severe ARDS (reduced pulmonary compliance) or elevated intra-abdominal hypertension impairs transmission of airway pressure to the intrathoracic vasculature.

---

4. Patient Blood Management (PBM): The Three Pillars

Patient Blood Management (PBM) is an evidence-based, multidisciplinary bundle designed to conserve patient red cell mass and improve outcomes without unnecessary allogeneic blood exposure.

                       [ THREE PILLARS OF PBM ]
                                   |
        +--------------------------+--------------------------+
        |                          |                          |
    [ PILLAR 1 ]               [ PILLAR 2 ]               [ PILLAR 3 ]
  Optimize Red Cell        Minimize Perioperative      Optimize Anemia
  Mass & Treat Anemia        Blood Loss               Tolerance & Triggers
        |                          |                          |
• Screen 3-4 wks prior     • Meticulous hemostasis    • Restrictive triggers
• Oral / IV iron therapy   • Tranexamic acid (TXA)      (Hb < 70-80 g/L)
• Treat B12 / Folate       • Cell salvage             • Acute MI: more liberal
• Erythropoiesis agents    • Normovolemic hemodilution  (Hb < 100 g/L, MINT)

Pillar 1: Detect and Treat Preoperative Anemia

• Anemia is present in up to $30-40\%$ of elective surgical patients and independently predicts 30-day mortality.
• Screen $3-4\text{ weeks}$ prior to surgery: serum ferritin, transferrin saturation (TSAT), renal function.
• Iron Deficiency Anemia (IDA): Absolute IDA (ferritin $<30\text{ }\mu\text{g/L}$) or functional IDA in chronic inflammation (ferritin $<100\text{ }\mu\text{g/L}$ with $\text{TSAT} < 20\%$) should be treated aggressively with intravenous iron (e.g., ferric carboxymaltose or ferric derisomaltose); IV iron bypasses hepcidin-mediated intestinal blockade and elevates hemoglobin by $15-30\text{ g/L}$ within $2-3\text{ weeks}$.

Pillar 2: Minimize Perioperative Blood Loss

1. Tranexamic Acid (TXA): A synthetic lysine analogue that competitively inhibits plasminogen activation and fibrin binding, halting fibrinolysis. Large randomized trials support its use: CRASH-2 (trauma) and WOMAN (postpartum haemorrhage) showed fewer deaths from bleeding when TXA was given within 3 hours, and POISE-3 (non-cardiac surgery) reduced a composite bleeding outcome, although non-inferiority for cardiovascular complications was not established. Surgical meta-analyses show reduced transfusion without a clear increase in thromboembolic events. Standard dose: $1\text{ g}$ or $10-15\text{ mg/kg}$ IV at induction, followed by an optional $1\text{ mg/kg/h}$ infusion.
2. Intraoperative Cell Salvage: Shed blood is aspirated from the surgical field, anticoagulated with heparinized saline, filtered, centrifuged to wash away free hemoglobin, stroma, and debris, and re-suspended in saline to yield packed red cells with a hematocrit of $50-70\%$. Contraindications: Contaminated bowel contents in field (unless specialized leukocyte reduction filters are used). Safely utilized in oncological surgery when using leukocyte depletion filtration.
3. Acute Normovolemic Hemodilution (ANH): Whole blood is collected from the patient immediately prior to surgery into standard citrate bags and replaced with crystalloid or colloid to maintain euvolemia. Blood lost during surgery has a lower hematocrit; the stored autologous blood (containing active platelets and clotting factors) is re-infused post-hemostasis.

Pillar 3: Optimize Physiological Tolerance to Anemia and Restrictive Triggers

• Restrictive Transfusion Strategy: Large-scale multicenter trials (TRICC, FOCUS, TRISS) confirm that a restrictive transfusion threshold of $Hb < 70-80\text{ g/L}$ ($7.0-8.0\text{ g/dL}$) is non-inferior or superior to a liberal threshold ($Hb < 100\text{ g/L}$) in stable critically ill and general surgical patients, significantly lowering nosocomial infections, transfusion-related circulatory overload (TACO), and transfusion-related acute lung injury (TRALI).
• Acute Myocardial Infarction Exception: In the MINT trial (2023; 3,504 patients with acute myocardial infarction and $Hb < 100\text{ g/L}$), a restrictive strategy (transfusion permitted below $80\text{ g/L}$) was followed by death or reinfarction at 30 days in $16.9\%$ versus $14.5\%$ with a liberal strategy (transfusion below $100\text{ g/L}$) (risk ratio 1.15, $p = 0.07$). Many clinicians therefore use a more liberal threshold, around $Hb < 100\text{ g/L}$, in acute myocardial infarction.

---

5. Viscoelastic Hemostatic Testing: ROTEM and TEG

Standard laboratory coagulation tests (PT/INR, aPTT, fibrinogen) are performed on cell-free, centrifuged plasma at $37^\circ\text{C}$ and require $45-60\text{ minutes}$, reflecting only initial thrombin generation. In contrast, viscoelastic tests—Rotational Thromboelastometry (ROTEM) and Thromboelastography (TEG)—provide point-of-care, real-time assessment of the entire clotting process in whole blood, evaluating platelet-fibrin interactions, clot elasticity, and hyperfibrinolysis within $10-15\text{ minutes}$.

                        [ ROTEM TRACING PARAMETERS ]

          CT
       [<--->]
       |     |
   ----+-----+-------------------
       |    / \                 |
       |   /   \                | MCF
       |  /     \---------------|---
       | /                      |
   ----+------------------------+-------------------
       | \     /----------------|---
       |  \   /                 |
       |   \ /                  |
   ----+----+-------------------
            [<->]
             CFT

ROTEM Assays

• EXTEM: Extrinsic pathway triggered by tissue factor; assesses factors VII, X, II, fibrinogen, and platelets.
• INTEM: Intrinsic pathway triggered by ellagic acid; assesses factors XII, XI, IX, VIII, X, II, fibrinogen, and platelets.
• FIBTEM: Extrinsic pathway (tissue factor) plus cytochalasin D, which selectively inhibits platelet cytoskeleton activation. Because platelets cannot contribute to clot firmness, the FIBTEM tracing isolates the pure contribution of fibrinogen to clot strength.
• APTEM: Extrinsic pathway with added aprotinin/tranexamic acid, which inhibits fibrinolysis in vitro; confirming hyperfibrinolysis if abnormal lysis in EXTEM normalizes in APTEM.
• HEPTEM: Intrinsic pathway with heparinase; eliminates heparin effect to detect true factor deficiency.

Viscoelastic Parameters, Interpretation, and Targeted Therapy